Amalgamated Bank Purchases 3,990 Shares of Catalent Inc (CTLT)
Amalgamated Bank grew its position in shares of Catalent Inc (NASDAQ:CTLT) by 28.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,046 shares of the company’s stock after purchasing an additional 3,990 shares during the quarter. Amalgamated Bank’s holdings in Catalent were worth $633,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in shares of Catalent by 66.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock valued at $173,000 after purchasing an additional 2,425 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after buying an additional 559 shares in the last quarter. Legato Capital Management LLC purchased a new stake in Catalent during the second quarter worth $204,000. Blair William & Co. IL purchased a new stake in Catalent during the second quarter worth $211,000. Finally, World Asset Management Inc purchased a new stake in Catalent during the second quarter worth $218,000.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Several analysts recently commented on the stock. BidaskClub upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Wells Fargo & Company upped their price objective on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 20th. Bank of America Corporation reissued a “buy” rating and set a $45.00 target price (up from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Zacks Investment Research raised shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 target price on the stock in a research note on Tuesday, July 4th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $45.00 target price on shares of Catalent in a research report on Tuesday, August 29th. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and a consensus price target of $38.64.
WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/03/amalgamated-bank-purchases-3990-shares-of-catalent-inc-ctlt.html.
Shares of Catalent Inc (CTLT) opened at 41.29 on Tuesday. Catalent Inc has a 1-year low of $21.83 and a 1-year high of $42.22. The stock’s 50 day moving average is $38.66 and its 200-day moving average is $34.48. The stock has a market cap of $5.17 billion and a PE ratio of 47.46.
Catalent (NASDAQ:CTLT) last posted its quarterly earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The firm had revenue of $616.90 million for the quarter, compared to the consensus estimate of $547.48 million. During the same period in the previous year, the business earned $0.52 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, analysts predict that Catalent Inc will post $1.62 EPS for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.